Benchmark Capital Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Benchmark Capital Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$398K	Sell	3,650 -350	-9%	-$43.8K	0.4%	62
2018 Q3	$646K	Buy	4,000 +2,000	+100%	+$273K	0.49%	59
2018 Q2	$264K	Sell	2,000 -15,250	-88%	-$1.44M	0.2%	99
2018 Q1	$1.28M	Sell	17,250 -4,000	-19%	-$267K	1.01%	29
2017 Q4	$1.18M	Buy	21,250 +850	+4%	+$45K	0.92%	34
2017 Q3	$925K	Buy	20,400 +10,400	+104%	+$416K	0.72%	44
2017 Q2	$337K	Buy	10,000 +2,500	+33%	+$81.4K	0.27%	89
2017 Q1	$222K	Hold	7,500	–	–	0.18%	103
2016 Q4	$206K	Buy	7,500 +2,500	+50%	+$100K	0.17%	105
2016 Q3	$307K	Sell	5,000 -57,150	-92%	-$1.73M	0.23%	90
2016 Q2	$1.19M	Sell	62,150 -7,200	-10%	-$133K	0.97%	34
2016 Q1	$1.35M	Buy	69,350 +17,600	+34%	+$308K	1.19%	29
2015 Q4	$2M	Sell	51,750 -800	-2%	-$25.9K	1.69%	19
2015 Q3	$1.69M	Sell	52,550 -35,800	-41%	-$1.21M	1.38%	25
2015 Q2	$2.69M	Sell	88,350 -3,200	-3%	-$65.4K	1.89%	12
2015 Q1	$1.22M	Sell	91,550 -700	-0.8%	-$9.33K	0.8%	39
2014 Q4	$1.33M	Buy	92,250 +38,000	+70%	+$643K	0.9%	35
2014 Q3	$1.15M	Buy	54,250 +19,350	+55%	+$437K	0.79%	43
2014 Q2	$1.04M	Hold	34,900	–	–	0.65%	55
2014 Q1	$839K	Sell	34,900 -8,000	-19%	-$204K	0.58%	60
2013 Q4	$874K	Buy	42,900 +21,250	+98%	+$631K	0.61%	55
2013 Q3	$1.02M	Sell	21,650 -400	-2%	-$15.4K	0.73%	46
2013 Q2	$839K	Buy	+22,050	New	+$789K	0.65%	52

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Benchmark Capital Advisors's SRPT Position: Q4 2018 in Review

Benchmark Capital Advisors reduced its Sarepta Therapeutics (SRPT) stake by 8.8% in Q4 2018, selling an estimated $43.8K and leaving 3,650 shares worth $398K. The position accounts for 0.4% of the portfolio, ranked #62.

Benchmark Capital Advisors first reported a position in SRPT in Q2 2013 and has held it in 23 quarters since. The position peaked at $2.69M in Q2 2015. 336 funds tracked by Wall St. Rank hold SRPT as of Q4 2018.

Benchmark Capital Advisors held 3,650 shares of Sarepta Therapeutics worth $398K as of Q4 2018.
Benchmark Capital Advisors sold 350 Sarepta Therapeutics shares in Q4 2018, an estimated $43.8K.
Sarepta Therapeutics made up 0.4% of Benchmark Capital Advisors's portfolio in Q4 2018, its #62 holding.
Benchmark Capital Advisors first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 23 quarters since.
Benchmark Capital Advisors's Sarepta Therapeutics position peaked at $2.69M in Q2 2015.
336 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2018.

Based on Benchmark Capital Advisors's 13F filing for Q4 2018, filed 11 Feb 2019.